Pazinib 400mg Tablet

Pazopanib 400mg Tablet is a protein kinase inhibitor that contains Pazopanib and is used to treat soft tissue sarcoma and kidney cancer.

Uses of Pazopanib 400mg Tablet

• Renal Cell Carcinoma
• Soft Tissue Sarcoma

How does Pazopanib 400mg Tablet work?

Pazopanib is a multi-kinase inhibitor of Vascular endothelial growth factor receptors, Platelet-derived growth factor receptors and Fibroblast growth factor receptors. Pazopanib blocks these pathways to slow tumor growth and prevent the formation of new blood vessels that tumors need to grow.

How to Use & Dosage

Pazopanib oral tablets are generally taken once a day. For optimal absorption, take it on an empty stomach, either one hour before meals or two hours after meals. The usual initial dose of pazopanib is 400 mg once daily, but this may vary according to the indication.

Take this medicine by mouth with a glass of water. Use the directions on the label of the medicine. Do not cut, crush or chew this medication. Take this medicine on an empty stomach, 1 hour before or 2 hours after meals. Do not take along with food.

Don’t take grapefruit juice with it. Take your medication regularly. Do not use this product more often than directed. Do not stop unless your doctor tells you to.

If you think you have used too much of this medicine go to the nearest poison control center or emergency room.

Possible Side Effects

• Hypertension (high blood pressure)
• Diarrhea
• Nausea
• Vomiting
• Dizziness
• Fatigue
• Liver function abnormalities
• Skin rash
• Severe liver damage

Safety Advise

🫁 Lung

It’s not known if it’s safe to take Pazinib in people with lung problems. Please discuss with your healthcare provider.

🫘 Kidney

It is not known whether Pazinib is safe for people who have kidney problems. Make sure to speak with your health care provider.

🫀 Liver

Pazinib might not be safe for people with liver problems. Ask your healthcare professional.

🤰 Pregnancy

It should be used during pregnancy only if clearly needed. Please consult your healthcare provider.

🤱 Breastfeeding

Pazinib may be unsafe to use while breastfeeding. Please speak with your health care professional.

Storage Instructions

Store at 30°C. Keep out of children and out of sunlight.

References

• VOTRIENT® (pazopanib) tablets, for oral use. Full Prescribing Information, including Boxed Warning. East Hanover, NJ: Novartis Pharmaceuticals Corporation (previously GlaxoSmithKline).
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 2010;28(6):1061-1068.
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet. 2012;379(9829):1879-1886.
• Shepard DR, Rini BI. Pazopanib: A Novel Multitargeted Tyrosine Kinase Inhibitor. Future Oncology. 2010;6(6):941-947.
• Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.